entertainment -WSS

entertainment

author：focus 2025-10-02 05:38:50 - browse：4423

One Medical and Amazon Care apps displayed on a phone. -- health tech coverage from STAT. — Adobe

The graveyard is littered with Amazon’s bets in health care: wearables, Care, the ill-fated Haven. Out of their ashes, a new health strategy has emerged at the tech goliath. And while its leaders insist that Amazon has no grand plan for health care, a flurry of moves in the last year offer a glimpse into its ambitions at a time when they seem more cohesive than ever.

“We have learned a lot in the years that we’ve been dabbling in health care,” said Sunita Mishra, chief medical officer for Amazon Health Services. “And it’s now made us more confident that we’re on the right track.”

STAT spoke to four of Amazon’s chief medical officers about the company’s recent plays and how they fit into the company’s health care goals. Last November, it launched Amazon Clinic, a marketplace for virtual-only appointments for straightforward medical needs like pink eye, UTIs, and birth control. Two months later, its Amazon Pharmacy business launched RxPass, a $5 generic medication discount program, setting it up as a Walmart rival. And in February, it closed the acquisition of hybrid primary care company One Medical in a deal valued at $3.9 billion.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Jerome Adams on the need for new antivirals for Covid
Next article： Readout Newsletter: Bristol, Sangamo, Gilead, and more

WSS

Bayer exec: U.S. is key in reviving beleaguered pharma’s drug pipeline

In boost for rare disease push, AstraZeneca to buy Amolyt Pharma

Acadia's Nuplazid fails as schizophrenia medicine in Phase 3 study

Change Healthcare outage fallout shows need for new oversight

Male and female sex labels in research insufficient, scientists say

Boston's new lab space is opening empty

knowledge

entertainment

focus

Malaria cases in Florida and Texas: Here’s what you need to know

Pushing for an NIH office for post

Activists slam private health insurers over coverage restrictions

Acadia's Nuplazid fails as schizophrenia medicine in Phase 3 study

Medicare proposal to cover medical devices draws a mixed reaction

Amylyx ALS drug fails trial: Relyvrio patients react with fear, worry

23andMe had bad news about my health. I wish a person had delivered it

Readout LOUD podcast: ALS dilemma, first MASH drug, and more

Virginia high school admissions case could be legal follow

Amylyx ALS drug fails trial: Relyvrio patients react with fear, worry

hotspot

Change Healthcare outage fallout shows need for new oversight

Ebola: Gilead Sciences antiviral shows promise as new treatment

Bayer exec: U.S. is key in reviving beleaguered pharma’s drug pipeline

Readout Newsletter: CAR

Why depression after traumatic brain injury is distinct

Readout LOUD podcast: ALS dilemma, first MASH drug, and more

leisure time

hotspot

knowledge

hotspot